A detailed history of Marshall Wace, LLP transactions in Amphastar Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 568,494 shares of AMPH stock, worth $25.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
568,494
Previous 227,127 150.3%
Holding current value
$25.4 Million
Previous $9.09 Million 203.68%
% of portfolio
0.04%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.99 - $50.09 $12.6 Million - $17.1 Million
341,367 Added 150.3%
568,494 $27.6 Million
Q2 2024

Aug 14, 2024

BUY
$38.65 - $43.48 $8.78 Million - $9.88 Million
227,127 New
227,127 $9.09 Million
Q1 2023

May 15, 2023

BUY
$27.99 - $37.92 $1.8 Million - $2.43 Million
64,209 New
64,209 $2.41 Million
Q3 2022

Nov 14, 2022

BUY
$27.56 - $37.75 $88,109 - $120,686
3,197 Added 11.24%
31,638 $890,000
Q2 2022

Aug 15, 2022

BUY
$29.79 - $42.29 $328,404 - $466,204
11,024 Added 63.29%
28,441 $989,000
Q1 2022

May 16, 2022

BUY
$22.96 - $36.45 $399,894 - $634,849
17,417 New
17,417 $625,000
Q3 2020

Nov 16, 2020

SELL
$17.99 - $22.22 $2.38 Million - $2.94 Million
-132,228 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$14.25 - $22.46 $2.42 Million - $3.81 Million
-169,682 Reduced 56.2%
132,228 $2.97 Million
Q1 2020

May 15, 2020

BUY
$12.66 - $20.08 $99,330 - $157,547
7,846 Added 2.67%
301,910 $4.48 Million
Q4 2019

Feb 14, 2020

SELL
$17.07 - $20.64 $2.04 Million - $2.46 Million
-119,229 Reduced 28.85%
294,064 $5.67 Million
Q3 2019

Nov 14, 2019

BUY
$19.12 - $22.62 $7.9 Million - $9.35 Million
413,293 New
413,293 $8.2 Million

Others Institutions Holding AMPH

About Amphastar Pharmaceuticals, Inc.


  • Ticker AMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,015,200
  • Market Cap $2.19B
  • Description
  • Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...
More about AMPH
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.